Live Prostate Health News
Continuously updated intelligence feed
Real-time medical news filtered and summarized by AI. Stay informed about prostate cancer, BPH, PSA testing, clinical trials, and the latest urology breakthroughs.
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
Updated analysis of the CAPItello-281 trial indicates a survival benefit for patients with specific genetic markers when treated with capivasertib.
Clinical Impact
Supports the use of targeted therapies for patients with specific genetic mutations in metastatic hormone-sensitive prostate cancer.
Patient-friendly explanation
For men with a specific genetic mutation, a new drug combination may help them live longer by targeting their cancer more effectively.
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
The FDA has approved the combination of Talazoparib and Enzalutamide for patients with specific genetic mutations in metastatic prostate cancer.
Clinical Impact
Expands the range of targeted therapies available for patients with HRR-mutated metastatic disease.
Patient-friendly explanation
The FDA has approved a new combination of two drugs to treat men with advanced prostate cancer who have specific genetic markers, offering a new way to fight the disease.
Study reveals a broad shift away from overtreatment of low-risk prostate cancer
New analysis of U.S. data shows a significant trend toward active surveillance rather than immediate aggressive treatment for low-risk prostate cancer.
Clinical Impact
Reduces the burden of unnecessary surgeries and radiation, improving quality of life for low-risk patients.
Patient-friendly explanation
Doctors are increasingly choosing to monitor low-risk prostate cancer closely rather than treating it immediately, which helps avoid unnecessary side effects.
FDA Approves Talazoparib Plus Enzalutamide for Metastatic, HRR+ APMN/S Prostate Cancer
The FDA has approved a combination therapy of talazoparib and enzalutamide for specific types of metastatic prostate cancer.
Clinical Impact
Provides a new standard-of-care option for patients with HRR-mutated prostate cancer.
Patient-friendly explanation
The FDA has approved a new combination of two medications to treat a specific type of advanced prostate cancer that has spread to other parts of the body.
Talazoparib/enzalutamide approved for HRR-mutated mAPMN/S prostate cancer
FDA approval granted for the combination of talazoparib and enzalutamide for patients with specific genetic mutations.
Clinical Impact
Provides a new standard-of-care combination therapy for patients with HRR-mutated metastatic prostate cancer.
Patient-friendly explanation
The FDA has approved a new combination of two drugs that work together to treat a specific type of advanced prostate cancer.
ESMO26: Combination therapies show promise in prostate cancer
New data from the ESMO 2026 congress highlights the potential of combination therapies and Syncromune’s SYNC-T vaccine for aggressive prostate cancer.
Clinical Impact
Provides new avenues for treating aggressive, hard-to-treat prostate cancer through immunotherapy and combination approaches.
Patient-friendly explanation
Researchers are testing new combinations of treatments and vaccines to help fight aggressive prostate cancer that is difficult to manage.
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
A Phase 1 study of JNJ-6143 showed a 75% tumor response rate and significant PSA reductions in patients with advanced prostate cancer.
Clinical Impact
Demonstrates the potential of a new RIPTAC platform to treat advanced prostate cancer by targeting specific protein interactions.
Patient-friendly explanation
A new experimental drug is showing promise in shrinking tumors and lowering PSA levels in patients who have already tried other treatments.
Diagnostic test could help doctors refine prostate cancer treatment
New research suggests that genomic testing (Decipher score) can help identify which high-risk patients benefit most from additional hormonal therapy.
Clinical Impact
Allows for personalized treatment plans, potentially sparing patients from unnecessary side effects.
Patient-friendly explanation
A genetic test can now help your doctor decide if you truly need extra hormone treatment, helping to avoid unnecessary side effects if your cancer is less aggressive.
AI Tool Shows Prostate Cancer Genetic Testing Feasibility in Community Care
A study demonstrates that AI-driven interpretation of NCCN guidelines can streamline genetic testing processes in community settings.
Clinical Impact
Reduces clinician burden and improves the accessibility of genetic testing for prostate cancer patients.
Patient-friendly explanation
A new computer tool is helping doctors more easily decide which patients should get genetic testing for prostate cancer, making the process faster and more accurate.
Top Poster Takeaways for Prostate Cancer from 2026 ESMO Congress
A summary of key research findings presented at the 2026 ESMO Congress regarding prostate cancer management and clinical outcomes.
Clinical Impact
Provides clinicians with the latest evidence-based updates to refine treatment strategies for advanced prostate cancer.
Patient-friendly explanation
Doctors recently shared new research findings at a major medical conference that could help improve how we treat prostate cancer.
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
Johnson & Johnson reported that their experimental once-daily oral drug successfully caused tumors to shrink or disappear in an early-stage clinical trial.
Clinical Impact
Provides a potential new oral treatment option for patients with prostate cancer, potentially improving convenience and efficacy.
Patient-friendly explanation
A new daily pill is showing promise in early tests by helping to shrink or eliminate prostate cancer tumors.
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
Findings from the ARACOG trial indicate that darolutamide may have a better cognitive safety profile compared to enzalutamide.
Clinical Impact
Influences drug selection for patients concerned about cognitive side effects during long-term treatment.
Patient-friendly explanation
A study suggests that one prostate cancer medication may be less likely to cause brain-related side effects like memory or focus issues compared to another common option.